283. 後天性赤芽球癆 Acquired pure red cell aplasia Clinical trials / Disease details

臨床試験数 : 19 / 薬物数 : 36 - (DrugBank : 23) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102

diseases per page:

Showing 1 to 10 of 19 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05559827 (ClinicalTrials.gov)	September 2022	14/9/2022	Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismat ...	Randomized Prospective Trial Evaluating the Efficacy of the antiCD38 Monoclonal Antibody Isatuximab ...	Immunological Pure Red Cell Aplasia	Drug: Isatuximab	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	15 Years	N/A	All	90	Phase 2	NULL
2	NCT04965597 (ClinicalTrials.gov)	April 19, 2022	21/6/2021	Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of ...	Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Mar ...	Bone Marrow Failure Syndrome;Congenital Amegakaryocytic Thrombocytopenia;Congenital Pure Red Cell Ap ...	Drug: Treosulfan;Drug: Fludarabine Phosphate;Drug: Tacrolimus;Drug: Methotrexate;Biological: Lapine T ...	Fred Hutchinson Cancer Center	Blood and Marrow Transplant Clinical Trials Network;National Cancer Institute (NCI);National Marrow ...	Recruiting	1 Year	49 Years	All	40	Phase 2	United States
3	NCT04423367 (ClinicalTrials.gov)	September 13, 2020	5/6/2020	Bortezomib Plus Dexamethasone for Acquired Pure Red Cell AplasiaFailure or Relapse After First-line ...	Safety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell AplasiaFailure or Re ...	Acquired Pure Red Cell Aplasia	Drug: bortezomib /dexamethasone	Institute of Hematology & Blood Diseases Hospital	NULL	Recruiting	18 Years	70 Years	All	17	Phase 2	China
4	NCT04470804 (ClinicalTrials.gov)	July 1, 2020	9/7/2020	Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA	Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Pros ...	Pure Red Cell Aplasia, Acquired	Drug: Sirolimus;Drug: Cyclosporine A	Bing Han	NULL	Completed	18 Years	88 Years	All	56	Phase 4	China
5	NCT03966053 (ClinicalTrials.gov)	September 13, 2019	23/5/2019	The Use of Trifluoperazine in Transfusion Dependent DBA	Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood C ...	Diamond Blackfan Anemia;Pure Red Cell Aplasia	Drug: Trifluoperazine	Adrianna Vlachos	NULL	Terminated	18 Years	65 Years	All	2	Phase 1/Phase 2	United States
6	NCT03918265 (ClinicalTrials.gov)	May 4, 2019	16/4/2019	Tacrolimus Treatment for Refractory Autoimmune Cytopenia	Tacrolimus Treatment for Refractory Autoimmune Cytopenia	Autoimmune Hemolytic Anemia;Pure Red Cell Aplasia;Evans Syndrome	Drug: Tacrolimus	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	80 Years	All	80	Phase 4	China
7	NCT03540472 (ClinicalTrials.gov)	June 10, 2018	14/5/2018	Tacrolimus Treatment for Refractory PRCA	Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study	Pure Red Cell Aplasia	Drug: tacrolimus	Peking Union Medical College Hospital	NULL	Unknown status	18 Years	80 Years	All	30	Phase 4	China
8	NCT03364764 (ClinicalTrials.gov)	February 1, 2018	21/11/2017	Sirolimus Treatment for Refractory PRCA	Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study	Pure Red Cell Aplasia	Drug: Sirolimus	Bing Han	NULL	Completed	18 Years	80 Years	All	64	Phase 4	China
9	NCT03333486 (ClinicalTrials.gov)	December 7, 2017	2/11/2017	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in T ...	A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripher ...	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Acute Leukemia in Remission;Acute ...	Drug: Cyclophosphamide;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Procedure: Pe ...	Roswell Park Cancer Institute	NULL	Active, not recruiting	1 Year	75 Years	All	31	Phase 2	United States
10	NCT03214354 (ClinicalTrials.gov)	July 5, 2017	5/7/2017	Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompati ...	A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in C ...	Sickle Cell Disease;Stem Cell Transplant Complications;Red Blood Cell Disorder;Pure Red Cell Aplasia ...	Drug: Alemtuzumab;Radiation: Total Body Irradiation;Drug: Sirolimus	University of Calgary	NULL	Recruiting	1 Year	19 Years	All	12	Phase 2	Canada

First Previous1 2Next Last